Use of ReDS Technology in Patients With Acute Heart Failure
Heart Failure, Lung Congestion
About this trial
This is an interventional treatment trial for Heart Failure focused on measuring Clinical trial, Lung congestion, Heart failure, Diuretics
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 18 years old
- Currently hospitalized for a primary diagnosis of HF, including symptoms and signs of fluid overload, regardless of left ventricular ejection fraction (LVEF), and a NT-proBNP concentration of ≥ 400 pg/L or a BNP concentration of ≥ 100 pg/L
Exclusion Criteria:
- Patient characteristics excluded from approved use of ReDS system: height <155cm or >190cm, BMI <22 or >39
- Patients discharged on inotropes, or with a left ventricular assist device or cardiac transplantation
- Congenital heart malformations or intra-thoracic mass that would affect right-lung anatomy
- End stage renal disease on hemodialysis
- Life expectancy <12 months due to non-cardiac comorbidities
- Participating in another randomized study
Sites / Locations
- Mount Sinai HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
ReDS-guided strategy
Standard of care strategy
For patients in this arm, daily measurements from the device will be revealed to the treating physician. Discharge can be planned when the clinical stability is achieved and the ReDS value is ≤35%. In case of a ReDS value >35%, treating physicians will follow a predefined algorithm before discharge to improve the results of ReDS test.
The drugs dosage, especially diuretics, will be selected according to the presence of symptoms and signs of systemic congestion and according to current recommendations. All the daily ReDS measurements will be blinded to the treating physician.